Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Abstract Background Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for stratified treatments allow clinical decision making in only a small minority of screened...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Erlend Skaga, Evgeny Kulesskiy, Marit Brynjulvsen, Cecilie J. Sandberg, Swapnil Potdar, Iver A. Langmoen, Aki Laakso, Emília Gaál-Paavola, Markus Perola, Krister Wennerberg, Einar O. Vik-Mo
פורמט: Artigo
שפה:Inglês
יצא לאור: Wiley 2019-12-01
סדרה:Clinical and Translational Medicine
נושאים:
Glioblastoma
Recurrent glioblastoma
Glioblastoma stem cells
High-throughput drug screening
Drug sensitivity and resistance testing
Individualized medicine
גישה מקוונת:http://link.springer.com/article/10.1186/s40169-019-0253-6
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים